3. Broader access to state prescription drug monitoring programs (PDMPs) will allow insurers to monitor for fraud, waste and abuse of controlled substances.
“This is also critical to allow clinically important coordination of care and discussions about potentially concerning combinations of controlled substances,” Kimberly Lenz, PharmD, clinical pharmacy manager in the UMass Medical School's Office of Clinical Affairs. “Very few states have granted insurers access to the PDMP. Washington State gave their Medicaid program access and noted several benefits, including, better treatment outcomes, better coordination of care, and reduction in costs by a reduction in medically unnecessary prescription drug use and diversion.”